CSIMarket


Freeline Therapeutics Holdings Plc  (FRLN)
Other Ticker:  
 


 

Freeline Therapeutics Holdings Plc

FRLN's Financial Statements and Analysis



Freeline Therapeutics Holdings Plc narrowed forth quarter of 2022 net loss per share of $-1.50 compare to net loss per share of $-3.93 recorded in the same quarter a year ago a decrease compare to $0.00 realized in previous quarter.


forth quarter of 2022
Earnings Per Share Revenues
$ -1.5 $  0 Mill
$+2.43     Unch.    



Freeline Therapeutics Holdings Plc's Revenue fell by 0 % in forth quarter of 2022 (Dec 31 2022) year on year, to $0 million and declined by sequentially.


Freeline Therapeutics Holdings Plc is

More on FRLN's Income Statement



Freeline Therapeutics Holdings Plc's in theforth quarter of 2022 recorded net loss of $-88.972 million, an improvement compare to net loss of $-140.391 million in IV. Quarter a year ago.

Sequentially company realized a net loss, compared to net income of $0.000 million in the previous quarter.

More on FRLN's Growth

Freeline Therapeutics Holdings Plc Inventories
In Dec 31 2022 company's net cash and cash equivalents decreased by $-70 million, capital expenditures fell by -4.27464.11%, to $-7 millions compare to same quarter a year ago

More on FRLN's Cash flow Statement


Freeline Therapeutics Holdings Plc does not pay out common stock dividend.

In trailing twelve-month period Freeline Therapeutics Holdings Plc payed $ -1.32 cash per share, on a free-cash flow basis .